Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Literature DB >> 26142442

MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma.

Emeline Tabouret¹, Françoise Boudouresque¹, Patrizia Farina¹, Maryline Barrié¹, Céline Bequet¹, Marc Sanson¹, Olivier Chinot¹.

Abstract

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2015 PMID： 26142442 PMCID： PMC4490881 DOI： 10.1093/neuonc/nov094

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

10 in total

1. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors: Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal: J Clin Oncol Date: 2010-05-10 Impact factor: 44.544

2. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.

Authors: Chandramu Chetty; Sajani S Lakka; Praveen Bhoopathi; Jasti S Rao
Journal: Int J Cancer Date: 2010-09-01 Impact factor: 7.396

3. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma.

Authors: Emeline Tabouret; Françoise Boudouresque; Maryline Barrie; Mona Matta; Celine Boucard; Anderson Loundou; Antoine Carpentier; Marc Sanson; Philippe Metellus; Dominique Figarella-Branger; L'houcine Ouafik; Olivier Chinot
Journal: Neuro Oncol Date: 2013-12-09 Impact factor: 12.300

4. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors: Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

5. A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245

6. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

Authors: Rose Du; Claudia Petritsch; Kan Lu; Patty Liu; Anna Haller; Ruth Ganss; Hanqiu Song; Scott Vandenberg; Gabriele Bergers
Journal: Neuro Oncol Date: 2008-03-21 Impact factor: 12.300

7. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors: K H Plate; G Breier; H A Weich; W Risau
Journal: Nature Date: 1992-10-29 Impact factor: 49.962

8. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544

9. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells.

Authors: G-One Ahn; J Martin Brown
Journal: Cancer Cell Date: 2008-03 Impact factor: 31.743

10. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544

10 in total

23 in total

1. Predicting glioblastoma response to bevacizumab through marker profiling?

Authors: Tobias Kessler
Journal: Neuro Oncol Date: 2016-02 Impact factor: 12.300

2. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.

Authors: Patrizia Farina; Emeline Tabouret; Pierre Lehmann; Maryline Barrie; Gregorio Petrirena; Chantal Campello; Celine Boucard; Thomas Graillon; Nadine Girard; Olivier Chinot
Journal: J Neurooncol Date: 2017-03-06 Impact factor: 4.130

3. Differentially Expressed Long Non-Coding RNAs Were Predicted to Be Involved in the Control of Signaling Pathways in Pediatric Astrocytoma.

Authors: Ruth Ruiz Esparza-Garrido; Juan Manuel Rodríguez-Corona; Javier Enrique López-Aguilar; Marco Antonio Rodríguez-Florido; Ana Claudia Velázquez-Wong; Rubí Viedma-Rodríguez; Fabio Salamanca-Gómez; Miguel Ángel Velázquez-Flores
Journal: Mol Neurobiol Date: 2016-10-13 Impact factor: 5.590

4. CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2.

Authors: Caren Yu-Ju Wu; Chia-Hua Chen; Chun-Yen Lin; Li-Ying Feng; Yung-Chang Lin; Kuo-Chen Wei; Chiung-Yin Huang; Jia-You Fang; Pin-Yuan Chen
Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300